Vermillion’s ovarian cancer program is directed at developing and commercializing novel high-value diagnostic tests that ultimately could lead to better patient outcomes through appropriate triage, earlier diagnosis, and optimal therapeutic selection.

In March, 2010, Vermillion launched OVA1^®, the first blood test cleared by the U.S. Food & Drug Administration (FDA) for the evaluation of an ovarian adnexal mass prior to a planned surgery. OVA1 utilizes a panel of five biomarkers that may help identify women with cancer so they can be referred directly to a gynecologic oncologist for their initial surgery. Guidelines from the American College of Obstetricians and Gynecologists (ACOG), the Society of Gynecologic Oncologists (SGO), and the National Comprehensive Cancer Network (NCCN) recommend that women with an ovarian adnexal mass that is suspicious for cancer be under the care of a gynecologic oncologist. Click here to learn more about this landmark test.